Biomarkers of Angiogenesis in Colorectal Cancer

Overview

Journal Biomark Cancer

Publisher Sage Publications

Date 2015 Nov 7

PMID 26543385

Citations 52

Authors

Luay Mousa

Mohamed E Salem

Sameh Mikhail

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10% of all new cancer diagnoses. Angiogenesis is a tightly regulated process that is mediated by a group of angiogenic factors such as vascular endothelial growth factor and its receptors. Given the widespread use of antiangiogenic agents in CRC, there has been considerable interest in the development of methods to identify novel markers that can predict outcome in the treatment of this disease with angiogenesis inhibitors. Multiple biomarkers are in various phases of development and include tissue, serum, and imaging biomarkers. The complexity of the angiogenesis pathway and the overlap between the various angiogenic factors present a significant challenge to biomarker discovery. In our review, we discuss the angiogenesis pathway and the most promising evolving concepts in biomarker discovery, as well as highlight the landmark studies that identify subgroups of patients with CRC who may preferentially benefit from angiogenesis inhibitors.

Citing Articles

Gold nanocomposites in colorectal cancer therapy: characterization, selective cytotoxicity, and migration inhibition.

Tan K, Chia L, Maki M, Cheah S, In L, Kumar P Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39878813 DOI: 10.1007/s00210-025-03839-z.

Genistein-Aspirin Combination Exerts Cytotoxic and Anti-Migratory Effects in Human Colorectal Cancer Cells.

Iftode C, Iurciuc S, Marcovici I, Macasoi I, Coricovac D, Dehelean C Life (Basel). 2024; 14(5).

PMID: 38792627 PMC: 11122532. DOI: 10.3390/life14050606.

Analyzing the Functional Roles and Immunological Features of Chemokines in COAD.

Xu H, Song Y Int J Mol Sci. 2024; 25(10).

PMID: 38791448 PMC: 11121388. DOI: 10.3390/ijms25105410.

Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.

Corrias G, Lai E, Ziranu P, Mariani S, Donisi C, Liscia N Cancers (Basel). 2024; 16(7).

PMID: 38611042 PMC: 11011199. DOI: 10.3390/cancers16071364.

Dysregulated Forkhead Box (FOX) Genes Association with Survival Prognosis, Anti-tumor Immunity, and Key Targeting Drugs in Colon Adenocarcinoma.

Xie Q, Wang J, Peng X Arch Iran Med. 2024; 26(9):510-528.

PMID: 38310407 PMC: 10862056. DOI: 10.34172/aim.2023.77.

References

Capirci C, Rampin L, Erba P, Galeotti F, Crepaldi G, Banti E . Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging. 2007; 34(10):1583-93. DOI: 10.1007/s00259-007-0426-1. View

Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92(6):735-45. DOI: 10.1016/s0092-8674(00)81402-6. View

Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T . Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. 2010; 103(9):1407-14. PMC: 2990609. DOI: 10.1038/sj.bjc.6605925. View

Zhang S, McCrudden C, Meng C, Lin Y, Kwok H . The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Onco Targets Ther. 2015; 8:835-43. PMC: 4403689. DOI: 10.2147/OTT.S80518. View

Sahani D, Kalva S, Hamberg L, Hahn P, Willett C, Saini S . Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology. 2005; 234(3):785-92. DOI: 10.1148/radiol.2343040286. View

Garcia-Carbonero R, Rivera F, Maurel J, Ayoub J, Moore M, Cervantes A . An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist. 2014; 19(4):350-1. PMC: 3983832. DOI: 10.1634/theoncologist.2014-0028. View

Jurgensmeier J, Schmoll H, ROBERTSON J, Brooks L, Taboada M, Morgan S . Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013; 108(6):1316-23. PMC: 3619270. DOI: 10.1038/bjc.2013.79. View

Kopetz S, Hoff P, Morris J, Wolff R, Eng C, Glover K . Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2009; 28(3):453-9. PMC: 2815707. DOI: 10.1200/JCO.2009.24.8252. View

Tsai H, Lin C, Huang C, Yang I, Yeh Y, Hsu W . Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients. Int J Clin Exp Pathol. 2015; 8(2):1900-10. PMC: 4396259. View

10.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M . Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2012; 381(9863):303-12. DOI: 10.1016/S0140-6736(12)61900-X. View

11.

Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D . VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol. 2011; 13(10):1202-13. PMC: 3261765. DOI: 10.1038/ncb2331. View

12.

Bellomi M, Petralia G, Sonzogni A, Giulia Zampino M, Rocca A . CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology. 2007; 244(2):486-93. DOI: 10.1148/radiol.2442061189. View

13.

Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis M . Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis. 2010; 26(2):143-51. DOI: 10.1007/s00384-010-1108-1. View

14.

Gagnon M, Bielenberg D, Gechtman Z, Miao H, Takashima S, Soker S . Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci U S A. 2000; 97(6):2573-8. PMC: 15970. DOI: 10.1073/pnas.040337597. View

15.

Lim S, Becker T, Chua W, Caixeiro N, Ng W, Kienzle N . Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. Cancer Lett. 2013; 346(1):24-33. DOI: 10.1016/j.canlet.2013.12.019. View

16.

Hong H, Kim S, Park H, Park M, Kim K, Kim W . Correlations of dynamic contrast-enhanced magnetic resonance imaging with morphologic, angiogenic, and molecular prognostic factors in rectal cancer. Yonsei Med J. 2012; 54(1):123-30. PMC: 3521250. DOI: 10.3349/ymj.2013.54.1.123. View

17.

Cohen S, Punt C, Iannotti N, Saidman B, Sabbath K, Gabrail N . Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(19):3213-21. DOI: 10.1200/JCO.2007.15.8923. View

18.

Harper S, Bates D . VEGF-A splicing: the key to anti-angiogenic therapeutics?. Nat Rev Cancer. 2008; 8(11):880-7. PMC: 2613352. DOI: 10.1038/nrc2505. View

19.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

20.

Cao Y . Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009; 2(59):re1. DOI: 10.1126/scisignal.259re1. View